SCHEMBL14716799

SCHEMBL14716799

N#CCC1CCN(c2ccc(Nc3nc(N4CCCCCC4)nc4cn[nH]c(=O)c34)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SYK P43405 13/20 1.00
JAK2 O60674 13/20 0.87
JAK1 P23458 1/20 0.86
TYK2 P29597 1/20 0.86
JAK3 P52333 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22101952 0.96 SYK (0.93) SYKJAK2JAK1TYK2JAK3
SCHEMBL14716645 0.93 SYK (1.00) SYKJAK2JAK1TYK2JAK3
Gusacitinib SCHEMBL29467492 0.92 SYK (1.00) SYKJAK2JAK1TYK2JAK3
Gusacitinib SCHEMBL14717111 0.92 SYK (1.00) SYKJAK2JAK1TYK2JAK3
SCHEMBL14716601 0.92 JAK2 (0.87) SYKJAK2JAK1TYK2JAK3
SCHEMBL20357871 0.92 SYK (0.86) SYKJAK2JAK1TYK2JAK3
SCHEMBL14717926 0.92 SYK (0.86) SYKJAK2JAK1TYK2JAK3
SCHEMBL14717827 0.92 JAK2 (0.86) SYKJAK2JAK1TYK2JAK3
Gusacitinib SCHEMBL25373888 0.92 SYK (0.98) SYKJAK2JAK1TYK2JAK3
SCHEMBL14717189 0.92 JAK2 (1.00) SYKJAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3392252-B1 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF LIBERTAS BIO INC (US) 2023-10-04 EP claimed
CN-108707151-B Pyrimido-pyridazinone compounds and uses thereof 阿萨纳生物科技有限责任公司 2022-06-03 CN claimed
US-20200190095-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF ABS DEVELOPMENT 1, INC. 2020-06-18 US claimed
US-10647720-B2 Pyrimido-pyridazinone compounds and methods of use thereof Asan BioSciences, LLC (US) 2020-05-12 US claimed
US-20190092779-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF Libertas Bio, Inc. 2019-03-28 US claimed
US-20190070182-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER ASANA BIOSCIENCES, LLC 2019-03-07 US claimed
US-10183944-B2 Pyrimido-pyridazinone compounds and methods of use thereof ASANA BIOSCIENCES, LLC (US) 2019-01-22 US claimed
EP-3404029-A2 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS AND USE THEREOF Asana BioSciences, LLC (US) 2018-11-21 EP claimed
EP-3392252-A1 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF Asana BioSciences, LLC (US) 2018-10-24 EP claimed
WO-2018187294-A1 PYRIMIDO-PYRIDAZINONE COMPOUND COMBINATIONS, METHODS, KITS AND FORMULATIONS THEREOF ASANA BIOSCIENCES, LLC (US) 2018-10-11 WO claimed
EP-2748166-B1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF ASANA BIOSCIENCES LLC (US) 2018-07-11 EP claimed
US-20170157126-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER ASANA BIOSCIENCES, LLC (US) 2017-06-08 US claimed
US-20160257691-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF Libertas Bio, Inc. 2016-09-08 US claimed
US-9382277-B2 Pyrimido-pyridazinone compounds and methods of use thereof ASANA BIOSCIENCES, LLC (US) 2016-07-05 US claimed
EP-2748166-A1 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF Endo Pharmaceuticals Inc. (US) 2014-07-02 EP claimed
US-8729079-B2 Pyrimido-pyridazinone compounds and methods of use thereof ENDO PHARMACEUTICALS INC. (US) 2014-05-20 US claimed
US-20130053346-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF ENDO PHARMACEUTICALS INC (US) 2013-02-28 US claimed
WO-2013028818-A1 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF ENDO PHARMACEUTICALS INC. (US) 2013-02-28 WO claimed
EP-4327886-A2 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF Libertas Bio, Inc. (US) 2024-02-28 EP disclosed
US-20130053346-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF ENDO PHARMACEUTICALS INC (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183944-B2 Pyrimido-pyridazinone compounds and methods of use thereof THPO, TYMP, TYMS SYK 741/4885JAK2 139/4885JAK1 173/4885
US-20190070182-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER MKI67, DPYD, TYMP SYK 919/4885JAK2 350/4885JAK1 627/4885
US-20160257691-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS SYK 741/4885JAK2 139/4885JAK1 173/4885
US-20170157126-A1 USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER MKI67, DPYD, TYMP SYK 919/4885JAK2 350/4885JAK1 627/4885
US-20190092779-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS SYK 741/4885JAK2 139/4885JAK1 173/4885
US-20200190095-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS SYK 741/4885JAK2 139/4885JAK1 173/4885
US-10647720-B2 Pyrimido-pyridazinone compounds and methods of use thereof THPO, TYMP, TYMS SYK 741/4885JAK2 139/4885JAK1 173/4885
US-20130053346-A1 PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF THPO, TYMP, TYMS SYK 741/4885JAK2 139/4885JAK1 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.